(TELK) - the company has surpassed expectations in each of the past 10 quarters, with seven of them registering double-digit surprises

Telik is a relatively early stage biotechnology company, so it doesn't have earnings yet. However, results thus far have been encouraging. Second-quarter results exceeded estimates by almost 15%. In fact, the company has surpassed expectations in each of the past 10 quarters, with seven of them registering double-digit surprises. Seven analysts have raised their numbers for this year, while four have done so for next year. Full Analysis Telik, Inc. (TELK), a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for the treatment of cancer and inflammatory diseases. Its lead product candidate TELCYTA is a small molecule cancer drug product designed to be activated in cancer cells. TELCYTA is in phase 3 clinical trials for the treatment of platinum resistant or refractory ovarian cancer and lung cancer. The company's other product TELINTRA is a small molecule bone marrow stimulant that activates signaling pathways and lead to the growth and differentiation of blood cells. The company is a relatively early stage biotechnology company, so it doesn't have earnings yet. However, results thus far have been encouraging. Second-quarter results exceeded estimates by almost 15%. In fact, the company has surpassed expectations in each of the past 10 quarters, with seven of them registering double-digit surprises. Seven analysts have raised their numbers for this year, while four have done so for next year. Another strength of the company is its strong cash position. As of June 30th of this year, TELK had almost $174 million in cash and cash equivalents on its balance sheet. It is important for biotechnology companies to have ample cash on hand in order to fund operations and invest in its future. During the second quarter the company began the Initiation of the ASSIST-5 Phase 3 clinical trial, which will compare treatment with the combination of TELCYTA and liposomal doxorubicin to treatment with liposomal doxorubicin alone in women with platinum refractory or resistant ovarian cancer in the second line setting. Content Courtesy: Zacks Investment Research #1 Ranked Stocks Highlight Archive To truly take advantage of the Zacks Rank, you need to first understand how it works. That is why we created the free special report: Zacks Rank Guide: Harnessing the Power of Earnings Estimate Revisions. | Blog Home| VitalStocks Home Tags: TELK, Telik, Stock-market, Stocks, Investing, Stock Trading, Business, Finance, Trading, Investing Newsletter, Stock Picks, earnings, analysts, analysts estimates